Aclaris Therapeutics, Inc. ACRS
We take great care to ensure that the data presented and summarized in this overview for Aclaris Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ACRS
View all-
Bml Capital Management, LLC Zionsville, IN14.3MShares$31.9 Million21.95% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA9.63MShares$21.6 Million0.04% of portfolio
-
Vivo Capital, LLC Palo Alto, CA8.89MShares$19.9 Million4.3% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD6.2MShares$13.9 Million0.61% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.67MShares$10.5 Million0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.33MShares$9.69 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.29MShares$7.38 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X02.8MShares$6.27 Million0.0% of portfolio
-
Marshall Wace, LLP London, X02.63MShares$5.9 Million0.01% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA2.39MShares$5.34 Million1.81% of portfolio
Latest Institutional Activity in ACRS
Top Purchases
Top Sells
About ACRS
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Insider Transactions at ACRS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 01
2025
|
James Loerop Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,447
-13.01%
|
$30,894
$2.48 P/Share
|
|
Feb 01
2025
|
James Loerop Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,500
+9.41%
|
-
|
|
Feb 01
2025
|
Kevin Balthaser Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,816
-6.08%
|
$11,632
$2.48 P/Share
|
|
Feb 01
2025
|
Kevin Balthaser Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,750
+13.36%
|
-
|
|
Feb 01
2025
|
Joseph Monahan Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,317
-4.65%
|
$22,634
$2.48 P/Share
|
|
Feb 01
2025
|
Joseph Monahan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,250
+4.45%
|
-
|
|
Feb 01
2025
|
Neal Walker INTERIM CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,559
-0.24%
|
$7,118
$2.48 P/Share
|
|
Feb 01
2025
|
Neal Walker INTERIM CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,467
+0.64%
|
-
|
|
Jan 02
2025
|
Neal Walker INTERIM CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
13,532
-0.92%
|
$27,064
$2.48 P/Share
|
|
Jan 02
2025
|
Neal Walker INTERIM CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
29,149
+1.95%
|
-
|
|
Jan 02
2025
|
James Loerop Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,575
-9.14%
|
$17,150
$2.48 P/Share
|
|
Jan 02
2025
|
James Loerop Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,150
+16.21%
|
-
|
|
Jan 02
2025
|
Kevin Balthaser Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,059
-5.88%
|
$10,118
$2.48 P/Share
|
|
Jan 02
2025
|
Kevin Balthaser Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,200
+13.31%
|
-
|
|
Jan 02
2025
|
Joseph Monahan Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,914
-3.88%
|
-
|
|
Jan 02
2025
|
Joseph Monahan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,380
+7.03%
|
-
|
|
Jan 01
2025
|
Neal Walker INTERIM CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,904
-0.27%
|
$7,808
$2.48 P/Share
|
|
Jan 01
2025
|
Neal Walker INTERIM CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,467
+0.65%
|
-
|
|
Jan 01
2025
|
Kevin Balthaser Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,430
-3.23%
|
$4,860
$2.48 P/Share
|
|
Jan 01
2025
|
Kevin Balthaser Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+9.07%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 770K shares |
|---|---|
| Open market or private purchase | 5.54M shares |
| Payment of exercise price or tax liability | 294K shares |
|---|---|
| Bona fide gift | 15K shares |